Visão geral da empresa
A life sciences entity, Quantum-Si incorporated focuses on developing a proprietary, universal, and single-molecule detection platform specifically applied to proteomics to facilitate next-generation protein sequencing. The company operates within the Healthcare sector and specializes in the Medical Devices industry, positioning itself to provide instruments capable of single-molecule detection with amino acid level resolution. Regarding its operational scale, the organization employs 145 individuals and maintains a total market capitalization of $165.33M alongside reported annual revenue of $2.44M for the trailing twelve months. These financial metrics indicate that the company operates as a micro-cap entity with very limited revenue generation relative to its market valuation, suggesting a high valuation multiple driven by potential future technology rather than current profitability. The disparity between the $165.33M market cap and the $2.44M revenue stream highlights a significant premium placed on the company's intellectual property and the anticipated market adoption of its Platinum and Platinum Pro NGPS instruments, rather than established cash flow.
Saúde financeira
For the trailing twelve months, the company reported revenue of $2.44M, a net income of -$101,339,000, and an EBITDA of -$92,594,000, revealing a substantial gap between top-line sales and bottom-line profitability. The massive negative net income relative to revenue indicates a cost structure burdened by significant expenses, likely including research and development costs or one-time charges that have decoupled net income from operational cash generation. Free cash flow stands at -$45,797,000, which signifies a negative financial flexibility where the company is consuming cash reserves to fund operations or capital expenditures rather than generating surplus liquidity. Gross margin is reported at 47.3%, suggesting that the cost of goods sold is less than half of the revenue, yet this does not offset the severe operating inefficiencies. Operating margin is -4677.2% and profit margin is 0.0%, figures that demonstrate extreme operational losses where expenses vastly exceed gross profit, rendering the company unable to convert sales into operational profit. The balance sheet shows cash holdings of $162.91M against total debt of $4.17M, resulting in a debt-to-equity ratio of 1.89. While the absolute debt level is low compared to cash, the high debt-to-equity ratio technically classifies the leverage profile as elevated in standard metrics, yet the massive cash buffer provides significant safety against refinancing risks. The current ratio is 7.64, indicating a highly conservative short-term liquidity position where current assets are more than seven times greater than current liabilities. Return on Equity is -46.5% and Return on Assets is -24.6%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns.
Avaliação de valorização
The trailing P/E ratio is N/A due to the negative net income, while the forward P/E is listed as -2.07, implying that the market is pricing in expected future losses or a significant turnaround in earnings trajectory. The price-to-book ratio is 0.75, indicating that the market values the company at 75% of its book value, which suggests the market is discounting the firm's assets or expecting future dilution. Price-to-sales is 67.87 and EV/EBITDA is -0.07, alternative metrics that suggest the market is willing to pay a very high multiple for every dollar of sales, driven almost entirely by the company's unique technology platform rather than earnings power. The 52-week high is $3.10 and the 52-week low is $0.76; without a specific current price provided in the data, the trading range indicates high volatility within a spread of $2.34 per share. The beta value is 3.08, which means the stock's price volatility is expected to be more than three times that of the broader market, making it an extremely aggressive investment vehicle. These valuation multiples combined with the high beta suggest the stock is priced for perfection and rapid future growth, rather than current financial fundamentals.
Growth & Income
Revenue growth year-over-year is -62.2% and earnings growth year-over-year is N/A, indicating a significant contraction in sales and the absence of a consistent earnings track record to measure growth velocity. The decline in revenue without a corresponding positive earnings growth suggests that the company is struggling to maintain its customer base or expand its addressable market in the current period. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company reinvests all available capital back into operations, research, or development rather than distributing income to shareholders. The overall growth and income profile is characterized by negative revenue momentum and a complete lack of dividend income, relying entirely on potential future product adoption to drive value creation.